June 9 (Reuters) – British drugmaker GSK on Tuesday agreed to acquire U.S.-listed cancer drug developer Nuvalent for $10.6 billion to boost its lung cancer portfolio. The all-cash deal values Nuvalent
(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)
Beauty and home care drive Unilever sales beat as food unit falters
By Yadarisa Shabong and Richa Naidu LONDON, Oct 28 (Reuters) - Unilever raised its annual…
Prostate cancer: Clues may help predict disease a decade in advance
Reporting by PA Media London (PA Media/dpa) - Scientists have discovered vital clues to help predict, more…
48 Amrita researchers feature in World’s Top 2% Scientists list
17 feature in the career-long category and 44 in the single-year category; 13 appear in…
